newsfilter
← Earnings
Earnings Releases·

Larimar Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Reported a net loss of $31.1 million ($0.29 per common share) for the third quarter of 2026, compared to a net loss of $47.7 million ($0.61 per common share) in the third quarter of 2025.
    • Reported a net loss of $93.5 million ($0.90 per common share) for the nine months ended September 30, 2026, compared to a net loss of $103.2 million ($1.50 per common share) for the same period in 2025.
    • Research and development expenses were $25.9 million for the third quarter of 2026, a decrease from $44.9 million in the third quarter of 2025, driven primarily by a $19.3 million decrease in drug manufacturing activities.
    • General and administrative expenses were $6.5 million for the third quarter of 2026, an increase from $4.6 million in the third quarter of 2025, due to acceleration of commercial activities.
    • For the nine months ended September 30, 2026, R&D expenses were $79.0 million (down from $94.9 million in 2025), while G&A expenses were $19.0 million (up from $13.6 million in 2025).
    • Cash, cash equivalents, and marketable securities totaled $128.7 million as of September 30, 2026, with a projected cash runway extending into late Q2 2027.
    • Total assets were $140.5 million as of September 30, 2026, compared to $145.8 million as of December 31, 2025.
    • Total liabilities were $39.0 million as of September 30, 2026, compared to $67.8 million as of December 31, 2025.
    • Stockholders' equity increased to $101.5 million as of September 30, 2026, from $78.1 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • Targets U.S. approval in mid-2027, contingent on FDA review.
    • Aims to launch in the U.S. in the third quarter of 2027, if approved.
    • Anticipates BLA submission acceptance in early 2027.
    • Plans to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if approved.
    • Scheduled to release an Open Label Study Safety Update in Q1 2027.
    • Management expects the next 12 months to bring pivotal registrational catalysts, including FDA review and progression of the FORWARD-FA Phase 3 study.
  • Business Segments and Product Lines:

    • Completed a rolling Biologics License Application (BLA) submission seeking accelerated approval for nomlabofusp for adults and pediatric patients with Friedreich's ataxia (FA).
    • The BLA submission utilizes FXN (skin frataxin) as a potential novel surrogate endpoint, which the FDA has indicated it is willing to consider.
    • Patients are currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp.
    • Presented open label study findings and new lipid and gene expression analyses at the 2026 International Congress for Ataxia Research (ICAR).
    • Enrollment continues in the open label study.
    • The company is preparing for a potential U.S. launch and evaluating options to support global commercialization.
  • Market and Competitive Landscape:

    • nomlabofusp is positioned as a potential first disease-modifying therapy to address the root cause of FA.
    • The company is developing its intracellular delivery platform to design fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds.
  • Risks and Challenges:

    • FDA may not agree with the development strategy or determine that skin FXN is not an acceptable surrogate endpoint for accelerated approval.
    • Completion of the BLA submission does not assure acceptance for filing or accelerated approval; the FDA may require additional information or studies.
    • Clinical trial results may differ from final results, and earlier data may not be predictive of later trial success.
    • Risks include delays in patient recruitment, adverse events, and changes in clinical protocols.
    • Dependence on third-party manufacturers to optimize and scale the manufacturing process.
    • Potential impact of public health crises on timelines and operations.
    • Uncertainty regarding the ability to raise necessary capital or successfully develop sales and marketing capabilities.
  • Management Commentary and Tone:

    • CEO Carole Ben-Maimon, M.D., described the BLA submission as a "major milestone" for the company and the FA community.
    • Management expressed being "energized by progress" across regulatory, clinical, and commercial plans.
    • The tone reflects confidence in the therapy's potential to alter the course of the disease by addressing its underlying cause.
    • Management is focused on bringing nomlabofusp to patients as a therapy designed to address the root cause of the disease.
  • Other Key Points:

    • The company has 104,634,619 common shares issued and outstanding as of September 30, 2026, compared to 83,090,392 as of December 31, 2025.
    • Preferred stock issuance increased to 500,000 shares issued and outstanding as of September 30, 2026, from 250,000 shares as of December 31, 2025.
    • The company is actively preparing for commercialization, evidenced by increased professional fees, legal fees, and compensation costs related to commercial headcount.
    • The press release includes forward-looking statements regarding the ability to develop, commercialize, and receive regulatory approval for nomlabofusp.
Company
LARIMAR THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology